Yearly Archives: 2012
Allon cuts staff and administrative costs
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today that, after the negative results in its pivotal davunetide study, it has implemented staff and administrative reductions. As part of this process approximately 40% of its staff has been terminated. These changes are consistent ... Continue reading
Posted in News Releases
Allon announces PSP clinical trial results
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today that its pivotal clinical trial evaluating its lead product candidate davunetide as a treatment for progressive supranuclear palsy (PSP) failed to demonstrate efficacy in this population. The study had co-primary outcome meas... Continue reading
Posted in News Releases
The United States, New Zealand & Mexico Issue Patent for New Allon Platform
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today that the United States, New Zealand and Mexican patent authorities have each issued composition of matter patents for a new family of peptides that the Company believes has the potential to be developed to treat neurological and... Continue reading
Posted in News Releases
Allon selected as Top 10 partnering prospect by CNS experts
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) was selected as one of the “Top 10 CNS Licensing Prospects” and will present today at the Windhover Therapeutics Area Partnerships (TAP) conference in Boston, MA . A panel of independent experts commissioned by the conference has selected Allo... Continue reading
Posted in News Releases
Allon files preliminary shelf prospectus
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) has filed a preliminary short form base shelf prospectus (the “Shelf Prospectus”) with the securities commissions in each province and territory of Canada (other than Quebec). Allon’s pivotal phase 2/3 clinical trial is evaluating lead neuropr... Continue reading
Posted in News Releases